IRVINE, Calif., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to participate in five upcoming investor conferences in November and December. The first conference is the Stephens Fall Investment Conference in New York. The Stephens conference will allow institutional investors to meet with Endologix but does not include a formal presentation.
Event: Stephens Fall Investment Conference
Date: Tuesday, November 13, 2012
The second conference is the Lazard Capital Markets 9th Annual Healthcare Conference in New York. The Lazard conference includes a formal presentation.
Event: Lazard Capital Markets 9th Annual Healthcare Conference
Date: Wednesday, November 14, 2012
Time: 10:30 a.m. ET
The third conference is the Piper Jaffray 24th Annual Healthcare Conference in New York. The Piper conference will utilize a fireside chat format for the presentation.
Event: Piper Jaffray 24th Annual Healthcare Conference
Date: Wednesday, November 28, 2012
Time: 11:00 a.m. ET
The fourth conference is the Capstone Investments One-on-One Conference in Boston. The Capstone conference will allow institutional investors to meet with Endologix but does not include a formal presentation.
Event: Capstone Investments One-on-One Conference in Boston
Date: Thursday, November 29, 2012
The fifth conference is the Oppenheimer 23rd Annual Healthcare Conference in New York. The Oppenheimer conference includes a formal presentation.
Event: Oppenheimer 23rd Annual Healthcare Conference
Date: Wednesday, December 12, 2012
Time: 1:35 p.m. ET
An audio webcast of the Company's presentations at the Lazard, Piper and Oppenheimer conferences will be available by visiting the investor relations section of Endologix's website at www.endologix.com. A replay of the presentations will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.